NuCelium

NuCelium is a clinical-stage biotechnology company and a member of the NantWorks ecosystem, focused on the development of next-generation allogeneic natural killer (NK) cell therapies. The company's core technology centers on a proprietary off-the-shelf NK cell platform designed to overcome the limitations of autologous cell therapies, such as high costs and complex manufacturing. By engineering NK cells to be universally applicable, NuCelium aims to provide immediate treatment options for patients with various cancers and infectious diseases. Their pipeline includes programs targeting solid tumors and viral infections, often evaluated in combination with other immunotherapies like IL-15 superagonists. NuCelium leverages the extensive research and manufacturing infrastructure of the Nant family of companies to accelerate the delivery of scalable cellular medicines. The company is led by Dr. Patrick Soon-Shiong and represents a key component of his vision for a comprehensive Cancer Moonshot infrastructure.